Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Ophthalmic Strategy

Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence

Eyes Post-Xtandi Revenues

  • Analysis

Executive Summary

Astellas set to acquire private US firm to add to its strategic capabilities in ophthalmology focus area, along with another revenue pillar as it prepares for Xtandi expiry. 

You may also be interested in...



Annexon’s ANX007 Misses GA Endpoint, But May Have Visual Acuity Path Forward

The ARCHER study did not show improvement in lesion growth, but still showed an improvement in best corrected visual acuity, potentially opening a pathway toward a pivotal trial.

Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate

In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: strong growth in blockbuster ranks in 2022; Lilly’s donanemab slow cognitive decline; FDA approves first RSV vaccine; Pfizer anticipates revenue bolus from vaccines; and Astellas buys into ophthalmology.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Commercial Ophthalmic Strategy
Latest Headlines

Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space

FDA’s Califf Defends CMS Drug Coverage Role, Blames Rx Industry Prices For US Health Woes

BIO Notebook: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird

Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy

See All
UsernamePublicRestriction

Register

SC148298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By